Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
AA4500 collagenase clostridium histolyticum · 1 trial · 1 indication
Total fixed flexion is defined as the sum of the fixed flexion contractures of the two joints receiving treatment. Change in fixed-flexion contracture is measured in degrees where a decrease of 100% would correspond to a reduction in contracture to 0 degrees
The total range of motion is the sum of the range of motion measurements of the two treated joints. Range of motion is defined as difference between full flexion angle and full extension angle expressed in degrees.
| Arm | Type | Description |
|---|---|---|
| AA4500 | EXPERIMENTAL | AA4500 collagenase clostridium histolyticum |
| Name | Type | Description |
|---|---|---|
| AA4500 collagenase clostridium histolyticum | BIOLOGICAL | 2 concurrent injections (0.58 mg) into 2 cords on the same hand |
Inclusion Criteria: 1. Provide written informed consent 2. Be a man or woman ≥ 18 years of age 3. Have a diagnosis of Dupuytren's disease and have at least 2 fixed-flexion contractures on the same hand that are ≥ 20º in PIP and/or MP joints in fingers, other than the thumbs, which are caused by pal...
AA4500 collagenase clostridium histolyticum is used for the treatment of Dupuytren's Contracture, a condition affecting the hand. It is a monoclonal antibody being developed for this musculoskeletal indication. The drug is currently in Phase 3 clinical development.
AA4500 collagenase clostridium histolyticum is being developed by BrainsWay Ltd., a company listed on the stock exchange under the ticker BWAY. The drug is currently in Phase 3 clinical development for the treatment of Dupuytren's Contracture.
AA4500 collagenase clostridium histolyticum is in Phase 3 clinical development. It is an investigational drug being studied for the treatment of Dupuytren's Contracture. The drug has completed one Phase 3 trial and is not yet approved.
AA4500 collagenase clostridium histolyticum has been studied in a Phase 3 clinical trial with the identifier NCT01407068. This trial, titled 'Administration of Two Injections for Multiple Dupuytren's Contractures,' was completed and enrolled 60 participants in the United States and Australia.
AA4500 collagenase clostridium histolyticum is a monoclonal antibody. It is being developed for the treatment of Dupuytren's Contracture, a musculoskeletal condition. The drug is currently in Phase 3 clinical development.